Ocugen, Inc identifies itself as a biopharmaceutical company focused on developing gene therapies to cure blindness and developing a vaccine to save lives from COVID-19. The company’s main developments are a modifier gene therapy platform based on nuclear hormone receptors (“NHRs”) to generate therapies for patient with inherited retinal diseases (“IRDs”) and dry age-related macular degeneration (“AMD”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.